Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 23, Issue 12, 1996, Pages 1641-1674

  Rigo, P ^a   Paulus, P ^a   Kaschten, B J ^b   Hustinx, R ^a   Bury, T ^a   Jerusalem, G ^a   Benoit, T ^a   Foidart Willems, J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Fluorine 18 fluorodeoxyglucose; Oncology; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADRENAL CORTEX CARCINOMA; BREAST CANCER; CANCER RECURRENCE; CANCER STAGING; COLORECTAL CARCINOMA; DIFFERENTIAL DIAGNOSIS; ESOPHAGUS CANCER; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; HYPOPHYSIS DISEASE; LIVER METASTASIS; LUNG CANCER; LYMPHOMA; MELANOMA; METHODOLOGY; MINIMAL RESIDUAL DISEASE; MUSCULOSKELETAL DISEASE; NEUROENDOCRINE DISEASE; ONCOLOGY; OVARY CARCINOMA; PANCREAS CANCER; PARATHYROID CARCINOMA; PLEURA CANCER; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PROGNOSIS; REVIEW; SCAR; STOMACH CANCER; THYROID CANCER; UROGENITAL TRACT CANCER;

DEOXYGLUCOSE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0030475781     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf01249629     Document Type: Review

References (375)

1. Phelps ME, Mazziotta J, Schelbert HR. Positron emission tomography and autoradiography. New York: Raven Press, 1986.
2. Wagner HN Jr. Nuclear medicine; what it is and what it does. In: Wagner HN Jr, Szabo Z, Buchanan JW, eds. Principles of nuclear medicine. New York: Williams-Saunders; 1995: 1-8.
3. Phelps ME, Huang SC, Hoffman EJ et al. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol 1979; 6: 371-388.
4. 18F)-fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ Res 1979; 44: 127-137.
5. Wagner HN Jr. Clinical PET: its time has come. J Nucl Med 1991; 32: 561-564.
6. Wahl RL. Positron emission tomography: application in oncology. In: Murray ICP, Ell PJ, eds. Nuclear medicine in clinical diagnosis and treatment. London: Churchill Livingstone; 1995: 801-820.
7. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991; 32: 623-648.
8. Reske SN, Bares R, Bull U et al. Klinkische Wertigkeit der Positronen-Emissions-Tomographie (PET) bei onkologischen Fragestellungen: Ergebnisse einer interdisziplinären Konsensuskonferenz (clinical value of positron emission tomography in oncology: results of an interdisciplinary consensus conference). Nucl Med 1996; 35: 42-52.
9. Warburg O, Wind F, Neglers E. On the metabolism of tumors in the body. In: Warburg O, ed. Metabolism of tumors. London: Constable; 1930: 254-270.
10. Som P, Atkins HL, Bandoypadhyay D, et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection. J Nucl Med 1980; 21: 670-675.
11. 18F- fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. Invest Radiol 1986; 22: 360-371.
12. Warburg O. The metabolism of tumors. New York: Smith RR; 1931: 129-169.
13. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-314.
14. Hatanaka M. Transport of sugar in tumor cell membranes. Biochem Biophys Acta 1974; 355: 77-104.
15. Hiraki Y, Rosen OM, Birnbaum MJ. Growth factors rapidly induce expression of the glucose transporter gene. J Biol Chem 1988; 27: 13 655-13 662.
16. Hiraki Y, De Herreros AG, Birnbaum MJ. Transformation stimulates glucose transporter gene expression in the absence of proteine kinase C. Proc Natl Acad Sci USA 1989; 86: 8252-8256.
17. Murakami T, Niushiyama T, Shirotani T et al. Identification of two enhancer elements in the gene encoding from the mouse which are responsive to serum, growth factor and oncogenes. J Biol Chem 1992; 267: 9300-9306.
18. Shawver LK, Olson SA, White MK, Weber MH. Degradation and biosynthesis of the glucose transporter protein in chicken embryo fibroblasts transformed by the src oncogene. Mol Cell Biol 1987; 7: 2112-2118.
19. Birnbaum MJ, Haspel HC, Rosen OM. Transformation of rat fibroblasts by FSV rapidly increases glucose transporter gene transcription. Science 1987; 235: 1495-1498.
20. Slater DW, Baldwin SA, Lienhard GE, Weber MJ. Proteins antigenically related to the human erythrocyte glucose transporter in normal and Rous sarcoma virus-transformed chicken embryo fibroblasts. Proc Natl Acad Sci USA 1982; 79: 1540-1544.
21. Godwin AK, Lieberman MW. Early and late responses to induction of ras T24 expression in Rat-1 cells. Oncogene 1990; 5: 1231-1241.
22. Godwin AK, Lieberman MW. Elevation of glucose transporter, C-myc and transin ARN levels by Ha-rasT24 is independent of its effect on the cell cycle. Mol Carcinogen 1991; 4: 275-285.
23. Sistonen L, Holtta E, Makela TP et al. The cellular response to induction of the P21c-Ha-ras oncoprotein includes stimulation of jun gene expression. EMBO J 1989; 9: 815-821.
24. Flier JS, Mueckler MM, Usher P, Lodish HF. Elevated levels of glucose transport and transporter messenger RNA are induced by ras and sarc oncogenes. Science 1987; 235: 1492-1495.
25. Hartung T, Büchler M, Grimmel S et al. Correlation of increased FDG-uptake and elevated expression of glucose transporter 1 gene in human pancreatic carcinoma. Eur J Nucl Med 1994; 21: S17.
26. Yamamoto T, Seino Y, Fukumoto H et al. Overexpression of facilitated glucose transporter genes in human cancer. Biochem Biophys Res Commun 1990; 170: 223-230.
27. Nishioka T, Oda Y, Seino Y et al. Distribution of the glucose transporters in human brain tumors. Cancer Res 1992; 52: 3972-3979.
28. Su TS, Tsai TF, Chi CW et al. Elevation of facilitated glucose transporter messenger RNA in human hepatocellular carcinoma. Hepatology 1990; 11: 118-122.
29. Monakhov NK, Neistadt EL, Shavlovskii MM et al. Physicochemical properties and isoenzyme composition of hexokinase for normal and malignant human tissues. J Natl Cancer Inst 1978; 61: 27-34.
30. Parry DM, Pederson PL. Intracellular localization and properties of particulate hexokinase in the Novikoff ascites tumor: evidence for an outer mitochondrial membrane location. J Biol Chem 1983; 258: 10 904-10 912.
31. Gallagher BM, Fowler JS, Gutterson NI et al. Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of F-18-2-deoxy-2-fluoro-D-glucose. J Nucl Med 1989; 19: 1154-1161.
32. 14C)-deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure and normal values on the conscious and anesthetized albino rat. J Neurochem 1977; 28: 897-916.
33. 18F)fluorodeoxyglucose and positron emission tomography. Neurology 1982; 32: 1323-1329.
34. 18F-fluorodeoxyglucose PET: characterization of the tumor and assessment of the effect of the treatment. J Nucl Med 1992; 33: 333-339.
35. Rodriguez M, Rehn S, Ahlstrom H et al. Predicting malignancy grade with PET in non-Hodgkin's lymphoma. J Nucl Med 1995; 36: 1790-1796.
36. Okada J, Yoshikawa K, Itami M et al. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med 1992; 33: 325-329.
37. 18F-FDG. J Comput Assist Tomogr 1990; 14: 960-962.
38. Adler LP, Blair HF, Makley JT et al. Noninvasive grading of muskuloskeletal tumors using PET. J Nucl Med 1991; 32: 1508-1512.
39. Sweeney MJ, Ashmore J, Morris HP, Klemi A. Comparative biochemistry of hepatomas. IV. Isotopes studies of glucose and fructose metabolism in liver tumors of different growth rates. Cancer Res 1963; 25: 995-1002.
40. Haberkorn U, Strauss LG, Reisser C et al. Glucose uptake, perfusion, and cell proliferation in head and neck tumors: relation of positron emission tomography to flow cytometry. J Nucl Med 1991; 32: 1548-1555.
41. Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure prolifetrative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med 1993; 34: 414-419.
42. Kubota R, Yamada S, Kubota K et al. Intratumoral distribution of flurorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiographic comparison with FDG. J Nucl Med 1992; 33: 1972-1980.
43. Minn H, Joensuu H, Ahonen A et al. Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors. Cancer 1988; 61: 1776-1781.
44. Minn H, Clavo AC, Grenman R et al. In vitro comparison of cell proliferation kinetics and uptake of tritiated fluorodeoxyglucose and L-methionine in squamous-cell carcinoma of the head and neck. J Nucl Med 1995; 36: 252-258.
45. 18F- fluorodeoxyglucose uptake in tumors: kinetic vs. steady-state methods with reference to plasma insulin. J Comput Assist Tomog 1993; 17: 115-123.
46. Wahl RL, Clavo AC. Effects of hypoxia on cultured human tumor cell uptake of thymidine, L-methionine and FDG. J Nucl Med 1993; 34: 73P.
47. Lindholm P, Minn H, Leskinen-Kallio S, Bergman J. Influence of the blood glucose concentration on FDG uptake in cancer. A PET study. J Nucl Med 1993; 34: 1-6.
48. Yao WJ, Hoh CK, Hawkins RA et al. Quantitative PET imaging of bone marrow glucose metabolic response to hematopoietic cytokines. J Nucl Med 1995; 36: 794-799.
49. Wahl RL, Quint LE, Greenough RL et al. Staging of mediastinal non-small cell lung cancer with FDG-PET, CT and fusion images: preliminary prospective evaluation. Radiology 1994; 191: 371-377.
50. 14C)methionine, (6-3H)thymidine, and gallium-67. J Nucl Med 1991; 32: 2118-2123.
51. Kubota R, Kubota K, Yamada S et al. Methionine uptake by tumor tissue: a microautoradiographic comparison with FDG. J Nucl Med 1995; 36: 484-492.
52. Ishiwata K, Ido T, Honda C et al. 4-Borono-2-(18F)fluoro-D,L- phenylalanine: a possible tracer for melanoma diagnosis with PET. Int J Radiat Appl Instrum 1992; 19: 311-318.
53. 14C)tyrosine for the investigation of a kinetic model to measure protein synthesis rates with PET. J Nucl Med 1988; 29: 524-529.
54. 14C-2-deoxyglucose. Radiology 1980; 134: 771-773.
55. Shields AT, Mankoff D, Graham MM et al. Analysis of 2-carbon-11-thymidine blood metabolites in PET imaging. J Nucl Med 1996; 37: 290-296.
56. Willemsen ATM, Vanwaarde A, Paans AMJ et al. In vivo protein synthesis rate determination in primary or recurrent brain tumors using L-[1-C-11]thyrosine and PET. J Nucl Med 1995; 36: 411-419.
57. DeGrado TR, Turkington TG, Williams JJ et al. Performance characteristics of a whole-body PET scanner. J Nucl Med 1994; 35: 1398-1406.
58. Wienhard K, Dahlbom M, Eriksson L et al. The ECAT EXACT high resolution 1 performance of a new high resolution positron scanner. J Comput Assist Tomogr 1994; 18: 110-118.
59. Karp JS, Muehllehner G, Mankoff DA et al. Continuous-slice PENN-PET: a positron tomograph with volume imaging capability. J Nucl Med 1990; 31: 617-627.
60. Macfarlane DJ, Cotton L, Ackermann RJ et al. Triple-head SPECT with 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG): initial evaluation in oncology and comparison with FDG PET. Radiology 1995; 194: 425-429.
61. Glass EC, Nelleman P, Hines H et al. Initial coincidence imaging experience with a SPECT/PET dual head camera. J Nucl Med 1996; 37: 53P.
62. Glaspy JA, Hawkins R, Hoh CK, Phelps ME. Use of positron emission tomography in oncology. Oncology 1993; 7: 41-50.
63. 137Cs source. Phys Med Biol 1995; 40: 929-944.
64. Lowe VJ, DeLong DM, Hoffman JM et al. Optimum scanning protocol for FDG-PET evaluation of pulmonary malignancy. J Nucl Med 1995; 36: 883-887.
65. Yu JN, Fahey FH, Harkness BA et al. Evaluation of emission-transmission registration in thoracic PET. J Nucl Med 1994; 35: 1777-1780.
66. Yu JN, Fahey FH, Gage HD et al. Intermodality, retrospective image registration in the thorax. J Nucl Med 1995; 36: 2333-2338.
67. Wu HM, Huang SC, Choi Y et al. A modeling method to improve quantitation of fluorodeoxyglucose uptake in heterogeneous tumor tissue. J Nucl Med 1995; 36: 297-306.
68. Hooper PK, Meikle SR, Eberl S, Fulham MT. Validation of postinjection transmission measurements for attenuation correction in neurological FDG-PET studies. J Nucl Med 1996; 37: 128-136.
69. Smith RJ, Karp JS. Attenuation correction in whole-body PET using short transmission scans. J Nucl Med 1996; 37: 172P.
70. Lowe VJ, Hoffman JM, DeLong DM et al. Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. J Nucl Med 1994; 35: 1771-1776.
71. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 1985; 5: 584-590.
72. Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology 1993; 189: 847-850.
73. Fischman AJ, Alpert NM. FDG-PET in oncology: there's more to it than looking at pictures. J Nucl Med 1993; 34: 6-11.
74. Minn H, Zasadny KR, Quint LE et al. Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET. Radiology 1995; 196: 167-173.
75. Gatenby RA. Potential role of FDG-PET imaging in understanding tumor-host interaction. J Nucl Med 1995; 36: 893-899.
76. Lindholm P, Leskinen-Kallio S, Kirvela O et al. Head and neck cancer: effect of food ingestion on uptake of C-11 methionine. Radiology 1994; 193: 863-867.
77. Minn H, Nuutila P, Lindholm P et al. In vivo effect of insulin on tumor and skeletal muscle glucose metabolism in patients with lymphoma. Cancer 1994; 73: 1490-1498.
78. Keyes JW Jr. SUV: standard uptake or silly useless value? J Nucl Med 1995; 36: 1836-1839.
79. Bischof-Delaloye A, Wahl RL. How high a level of FDG abdominal activity is considered normal? J Nucl Med 1995; 36: 106P.
80. Meyer MA. Diffusely increased colonic F-18 FDG uptake in acute enterocolitis. Clin Nucl Med 1995; 20: 434-435.
81. Pietrzyk Y, Scheidhauver K, Scharl A et al. Presurgical visualization of primary breast carcinoma with PET emission and transmission imaging. J Nucl Med 1995; 36: 1882-1884.
82. Wagner HN Jr. Positron emission tomography at the turn of the century. A perspective. Semin Nucl Med 1992; 22: 285-288.
83. Hoh CK, Hawkins RA, Glaspy J et al. Cancer detection with whole-body PET using 2-(F-18)-fluoro-2-deoxy-D-glucose. J Comput Assist Tomogr 1993; 17: 582-589.
84. Lagrange JL, Maublant J, Darcourt J. Positron emission tomography: role of F-18 fluorodeoxyglucose imaging in oncology. Bull Cancer (Paris) 1995; 82: 611-622.
85. Rigo P, Paulus P, Jerusalem G et al. Indications cliniques de la tomographie à positons au 18-FDG en oncologie. Expérience préliminaire et revue de la littérature. Médecine Nucléaire - Imagerie Fonctionnelle et Métabolique 1995; 19: 73-89.
86. Shulkin BL, Mitchell DS, Ungar DR et al. Neoplasms in a pediatric population: 2-[F-18]-fluoro-2-deoxy-D-glucose PET studies. Radiology 1995; 194: 495-500.
87. Kole AC, Nieweg OE, Pruim J et al. Whole body PET with FDG: detection of unknown primary tumors. J Nucl Med 1995; 36: 57P.
88. Kim EE, Chung SK, Haynie TP et al. Differentiation of residual or recurrent tumors from post-treatment changes with F-18 FDG PET. Radiographics 1992; 12: 269-279.
89. Di Chiro G, Brooks RA. PET-FDG of untreated and treated cerebral gliomas. J Nucl Med 1988; 29: 421-422.
90. Di Chiro G, Oldfield E, Wright DC et al. Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. Am J Roentgenol 1988; 150: 189-197.
91. Strauss LG, Clorius JH, Schlag P et al. Recurrence of colorectal tumors: PET evaluation. Radiology 1989; 170: 329-332
92. Coleman RE, Cascade E, Gupta NC et al. Clinical application and economic implications of PET in the assessment of solitary pulmonary nodules. A retrospective study. Abstract from the 1994 ICP Meeting, Institute for Clinical PET, Fairfax, Virginia.
93. Alavi JB, Alavi A, Chawluk J et al. Positron emission tomography in patients with glioma: a predictor of prognosis. Cancer 1988; 62: 1074-1078.
94. Reisser C, Haberkorn U, Strauss LG. The relevance of positron emission tomography for the diagnosis and treatment of head and neck tumors. J Otolaryngol 1993; 22: 231-238.
95. Quint LE, Francis IR, Wahl RL et al. Preoperative staging of non-small-cell carcinoma of the lung: imaging methods. Am J Roentgenol 1995; 164: 1349-1359.
96. Khouri NF et al. The solitary pulmonary nodule, assessment, diagnosis and management. Chest 1987; 91: 128-133.
97. Midthun DE, Swensen SJ, Pett JR. Clinical strategies for solitary pulmonary nodules. Ann Rev Med 1992; 93: 195-208.
98. Kubota K, Matsuzawa T, Fujiwara T et al. Differential diagnosis of lung tumor with positron emission tomography: a prospective study. J Nucl Med 1990; 31: 1927-1992.
99. Dewan NA, Gupta NC, Redepenning LS et al. Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Chest 1993; 104: 997-1002.
100. Patz EL, Lowe VJ, Hoffman JM et al. Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 1993; 188: 487-490.
101. Slosman DO, Spiliopoulos A, Couson F et al. Satellite PET and lung cancer: a prospective study in surgical patients. Nucl Med Commun 1993; 14: 955-961.
102. Gupta NC, Frank AR, Dewan NA et al. Solitary pulmonary nodules: detection of malignancy with PET with 2-(F-18)-fluoro-2-deoxy-D-glucose. Radiology 1992; 184: 441-444.
103. Gupta N, Chandramouli B, Reeb S, Dewan N. Diagnostic evaluation of solitary pulmonary nodules using PET-FDG imaging. J Nucl Med 1994; 35: 76P.
104. 18F] fluorodeoxyglucose. Ann Thorac Surg 1994; 58: 698-703.
105. Dewan NA, Reeb SD, Gupta NC et al. PET-FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions. A comparative risk-benefit analysis. Chest 1995; 108: 441-446.
106. Bury T, Paulus P, Corhay JL et al. Apport diagnostique de la tomographie à émission de positons dans l'évaluation d'une opacité pulmonaire unique: étude préliminaire chez 30 patients. Médecine Nucléaire, Imagerie Fonctionnelle et Métabolique 1996; 20: 77-82.
107. Bury T, Dowlati A, Paulus P et al. Evaluation of the solitary pulmonary nodule by positron emission tomography imaging. Eur Respir J 1996; 9: 410-414.
108. Bury T, Corhay JL, Paulus P et al. Evaluation du nodule pulmonaire solitaire par la tomographie à émission de positons au 18-FDG. Rev Mal Respir 1995; 12: R81.
109. Kazerooni EA, Lim FT, Mikhail A, Martinez FJ. Risk of pneumothorax in CT-guided transthoracic needle aspiration biopsy of the lung. Radiology 1996; 198: 371-375.
110. Berlangieri SU, Scott AM, Knight S et al. Mediastinal lymph node staging in non-small cell lung carcinoma: comparison of F-18-FDG positron emission tomography with surgical pathology. Eur J Nucl Med 1994; 21: S62.
111. Sasaki M, Ichiya Y, Kuwabara Y et al. The usefulness of FDG-PET for the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer. A comparative study with x-ray CT. Eur J Nucl Med 1994; 21: S189.
112. Patz EF, Lowe VJ, Hoffman JM et al. Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-(F-18)-2-deoxy-D-glucose. Radiology 1994; 191: 379-382.
113. Patz EF Jr, Lowe VJ, Goodman PC, Herndon J. Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma. Chest 1995; 108: 1617-1621.
114. Buchpiguel CA, Tse K, Alavi A et al. Use of quantitative FDG-PET whole body imaging in staging lung cancer. A comparison with CT. Eur J Nucl Med 1994; 21: S61.
115. 18F- fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet 1994; 344: 1265-1266.
116. Chin R Jr, Ward R, Keyes JW et al. Mediastinal staging of non-small-cell lung cancer with positron emission tomography. Am J Resp Crit Care Med 1995; 152: 2090-2096.
117. Valk PE, Pounds TR, Hopkins DM et al. Staging non-small cell lung cancer by whole-body positron emission imaging. Ann Thorac Surg 1995; 60: 1573-1582.
118. Bury T, Dowlati A, Paulus P et al. Positron emission tomography versus computed tomography in the staging of mediastinal non-small cell lung cancer. Eur Respir J 1995; 22: 846.
119. Bury T, Corhay JL, Paulus P et al. La tomographie à émission de positons dans l'évaluation de l'extension ganglionnaire intrathoracique du cancer bronchique non grain d'avoine: étude préliminaire chez 30 patients. Rev Mal Respir 1996; 9: 410-414.
120. Bury T, Paulus P, Benoit T et al. Positron emission tomography versus computed tomography in the staging of mediastinal non-small cell lung cancer. Eur J Nucl Med 1995; 22: 846.
121. Boland GW, Goldberg MA, Lee MJ et al. Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-deoxy-D-glucose. Radiology 1995; 194: 131-134.
122. 18FDG-PET. Eur J Nucl Med 1996; 23: 204-206.
123. Larcos G, Maisey MN. FDG-PET screening for cerebral metastasis in patients with suspected malignancy. Nucl Med Commun 1996; 17: 197-198.
124. 18F-2-fluoro-2-deoxy-D-glucose and positron emission tomography: preliminary study of lung cancer. Intl J Radiat Oncol Biol Phys 1990; 19: 1005-1010.
125. Knopp MV, Bischoff H, Rimac A et al. Clinical utility of positron emission tomography with FDG for chemotherapy response monitoring - a correlative study of patients with small cell lung cancer. J Nucl Med 1994; 35: 75P.
126. Hubner KF, Smith GT, Raja S et al. Positron emission tomography for evaluating chest masses. J Nucl Med 1994; 35: 220P.
127. Hubner KF, Buonocore E, Singh SK et al. Characterization of chest masses by FDG positron emission tomography. Clin Nucl Med 1995; 20: 293-298.
128. Inoue T, Kim EE, Komaki R et al. Detecting recurrent or residual lung cancer with FDG-PET. J Nucl Med 1995; 36: 788-793.
129. Duhaylongsod FG, Lowe VJ, Patz EF et al. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG-PET). J Thorac Cardiovasc Surg 1995; 110: 139-140.
130. Frank A, Lefkowitz D, Jaeger S et al. Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings. Int J Radiat Oncol Biol Phys 1995; 32: 1495-1512.
131. Bury T, Paulus P, Weber T et al. Potential interest of pleural diseases evaluation with FDG-PET imaging: preliminary report. Eur J Nucl Med 1996; 23: 1186.
132. Lowe VJ, Patz E, Harris L et al. FDG-PET evaluation of pleural abnormalities. J Nucl Med 1994; 35: 228P.
133. Rege SD, Hoh CK, Glaspy JA et al. Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodeoxyglucose. Cancer 1993; 72: 82-90.
134. Rhodes CG, Hughes JM. Pulmonary studies using positron emission tomography. Eur Respir J 1995; 8: 1001-1017.
135. Slosman DO, Spiliopoulos A, Keller A et al. Quantitative metabolic PET imaging of a plasma cell granuloma. J Thorac Imaging 1994; 9: 116-119.
136. Tse KKM, Buchpiguel CA, Alavi JB et al. Detection and semi-quantitative measurement of lung cancer metabolic activity by whole body PET-FDG imaging. J Nucl Med 1994; 35: 226P.
137. August DA, Ottow RT, Sugarbaker PH. Clinical perspectives on human colorectal cancer metastases. Cancer Metastasis Rev 1984; 3: 303-324.
138. Moertel CG et al. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 1993; 270: 943-947.
139. Cheu YM et al. Recurrent colorectal carcinoma. Evaluation with barium enema examination and CT. Radiology 1987; 163: 307-310.
140. Moss MA. Imaging of colorectal carcinoma. Radiology 1989; 170: 308-310.
141. 18F)fluoro-D-glucose in liver metastases from colon carcinoma. J Nucl Med 1982; 23: 1133-1137.
142. Falk PM, Gupta NC, Thorson AG et al. Positron emission tomography for preoperative staging of colorectal carcinoma. Dis Colon Rectum 1994; 37: 153-156.
143. Gupta NC, Falk PM, Frank AL et al. Pre-operative staging of colorectal carcinoma using positron emission tomography. Nebr Med J 1993; 30-35.
144. Schlag P, Lehner B, Strauss LG et al. Scar or recurrent rectal cancer. Arch Surg 1989; 124: 197-200.
145. Ito K, Kato T, Tadokoro M et al. Recurrent rectal cancer and scar: differentiation with PET and MR imaging. Radiology 1992; 182: 549-552.
146. Schiepers C, Penninckx F, De Vadder N et al. Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur J Surg Oncol 1995; 21: 517-522.
147. Grabbe E, Winkler R. Local recurrence after sphincter-saving resection for rectal and rectosigmoid carcinoma: value of various diagnostic methods. Radiology 1985; 155: 305-310.
148. 18F-fluorodeoxyglucose in recurrent colorectal cancer. Br J Surg 1994; 81: 1666-1671.
149. Gupta NC, Bowman BM, Frank AL et al. PET-FDG imaging for follow-up evaluation of treated colorectal cancer. Radiology 1991; 199: 181P.
150. Gupta N, Bradfield H. Role of positron emission tomography scanning in evaluating gastrointestinal neoplasms. Semin Nucl Med 1996; 26: 65-73.
151. Pounds TR, Valk PE, Haseman MK et al. Whole-body PET-FDG imaging in diagnosis of recurrent colorectal cancer. J Nucl Med 1995; 36: 57P.
152. Bohdiewicz PJ, Juni JE, Ball D, Dworkin H. Krukenberg tumor and lung metastases from colon carcinoma diagnosed with F-18 FDG PET. Clin Nucl Med 1995; 20: 419-420.
153. Bohdiewicz PJ, Scott GC, Juni JE et al. Indium-111 OncoScinti CR/OV and F-18 FDG in colorectal and ovarian carcinoma recurrences. Early observations. Clin Nucl Med 1995; 20: 230-236.
154. Daenen F, Hustinx H, Paulus P et al. Detection of recurrent colorectal carcinoma with whole-body FDG PET. J Nucl Med 1996; 37; 261P.
155. Larson SM, Cohen AM, Cascade MBA. Clinical application and economic implications of PET in the assessment of colorectal cancer recurrence: a retrospective study. Abstract from the 1994 ICP Meeting, Institute for Clinical PET, Fairfax, Virginia.
156. Haberkorn U, Strauss L, Dimitrakopoulou A et al. PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med 1991; 32: 1485-1490.
157. Engenhart R, Kimmig BN, Straub LG et al. Therapy monitoring of presacral recurrences after high-dose irradiation: value of PET, CT, CEA and pain score. Strahlenther Onkol 1992; 168: 203-212.
158. Hawkins R. Pancreatic tumors: imaging with PET. Radiology 1995; 95: 320-322.
159. Megibow AJ, Zhou XH, Rotterdam H et al. Pancreatic adenocarcinoma: CT versus MR imaging in the evaluation of resectability - Report of the Radiology Diagnostic Oncology Group. Radiology 1995; 195: 327-332.
160. Syrota A, Duquesnoy N, Paraf M et al. The role of positron emission tomography in the detection of pancreatic disease. Radiology 1992; 143: 249-253.
161. Kirchner PT, Ryan J, Zalutsky M et al. Positron emission tomography for the evaluation of pancreatic disease. Semin Nucl Med 1980; 10: 374-391.
162. Kubo S, Yamamoto K, Magata Y et al. Assessment of pancreatic blood flow with positron emission tomography and oxygen-15-water. Ann Nucl Med 1991; 5: 133-138.
163. Bares R, Klever P, Hauptmann S et al. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology 1994; 192: 79-86.
164. 18F]-fluoro-2-deoxy-D-glucose positron emission tomography. Gut 1995; 365: 771-777.
165. Inokuma T, Tamaki N, Torizuka T et al. Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US. Radiology 1995; 195: 345-352.
166. Inokuma T, Tamaki N, Torizuka T et al. Value of fluorine-18- fluorodeoxyglucose and thallium-201 in the detection of pancreatic cancer. J Nucl Med 1995; 36: 229-235.
167. Klever P, Bares R, Fass J et al. PET with fluorine 18 deoxyglucose for pancreatic disease. Lancet 1992; 340: 1158-1159.
168. Stollfuss JC, Glatting G, Friess H et al. 2-(fluorine-18)-fluoro-2-deoxy- glucose PET in detection of pancreatic cancer: value of quantitative image interpretation. Radiology 1995; 195: 339-344.
169. 18F-fluorodeoxyglucose with magnetic resonance images in patients with pancreatic carcinoma. Nucl Med Commun 1995; 16: 575-580.
170. 18F- fluorodeoxyglucose. J Jpn Surg Soc 1994; 95: 317-325.
171. Yasuda S, Raja S, Hubner KF. Application of whole-body positron emission tomography in the imaging of esophageal cancer: report of a case. Surgery Today 1995; 25: 261-264.
172. Baker ME, Pelley R. Hepatic metastases: basic principles and implications for radiologists. Radiology 1995; 197: 329-337.
173. Ohashi I, Hanafusa K, Hanafusa K, Yoshida T. Small hepatocellular carcinomas: two-phase dynamic incremental CT in detection and evaluation. Radiology 1993; 189: 851-855.
174. Hollett MD, Jeffrey RB Jr, Nino-Murcia M et al. Dual-phase helical CT of the liver: value of arterial phase scans in the detection of small (≤1.5 cm) malignant hepatic neoplasms. AJR 1995; 164: 879-884.
175. Gupta N, Frank A, Mailliard J et al. Accurate detection of liver metastases in patients with primary malignancies using PET-FDG imaging. J Nucl Med 1993; 34: 6P.
176. Shields AT, Graham MM, Helton S et al. Utility F-18 FDG PET in preoperative evaluation of patients with colon carcinoma metastatic to liver. J Nucl Med 1995; 36: 106P.
177. Hustinx R, Paulus P, Daenen F et al. PET imaging of liver metastases: a retrospective study. J Nucl Med 1996; 37: 250P.
178. Messa C, Choi Y, Ho C et al. Quantitative evaluation of glucose utilization in liver metastases, parametric imaging of FDG uptake with PET. J Comput Assist Tomogr 1992; 16: 684-689.
179. 18F-FDG positron emission tomography. J Comput Assist Tomogr 1990; 14: 370-374.
180. Enomoto K, Fukanaga T, Okazumi S et al. Can fluorodeoxyglucose-positron emission tomography evaluate the functional differentiation of hepatocellular carcinoma? Kaku Igaku 1991; 28: 1353-1356.
181. Torizuka T, Tamaki N, Inokuma T et al. Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy. J Nucl Med 1994; 35: 1965-1969.
182. Torizuka T, Tamaki N, Inokuma T et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 1995; 36: 1811-1817.
183. Paul R. Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma. J Nucl Med 1987; 28: 288-292.
184. Bares R, Horstmann K, Altehoefer C et al. F-18 deoxyglucose (FDG) PET to assess local effects of radiation or chemotherapy in patients with malignant lymphoma. J Nucl Med 1991; 32: 918.
185. Newman JS, Francis IR, Kaminski MS, Wahl RL. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology 1994; 190: 111-116.
186. Lapela L, Leskinen S, Minn HR et al. Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood 1995; 86: 3522-3527.
187. Okada J, Yoshikawa K, Imazeki K et al. The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis. J Nucl Med 1991; 32: 686-691.
188. 18F-fluorodeoxyglucose in the staging of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med 1995; 22: 786.
189. Jerusalem G, Fassotte MF, Paulus P et al. Whole-body positron emission tomography for staging, response evaluation and follow-up of Hodgkin's disease and non-Hodgkin lymphoma. Blood 1995; 86 Suppl 1: 534a.
190. Royal HD. Clinical applications of positron emission tomography in
191. Yoshikawa K, Okada J, Uno K et al. Evaluation of therapeutic effect on the malignant lymphoma by dynamic positron emission tomographic technique using fluorine-18 2-deoxy-2-fluoro-D-glucose. J Nucl Med 1989; 30: 910.
192. Hoekstra OS, Ossenkoppele GJ, Golding R et al. Early treatment response in malignant lymphoma as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. J Nucl Med 1993; 34: 1706-1710.
193. Bares R, Altehoefer C, Cremerius U et al. FDG-PET for metabolic classification of residual lymphoma after chemotherapy. J Nucl Med 1994; 35: 131P.
194. Okada J, Oonishi H, Yoshikawa K., et al. FDG-PET for predicting the prognosis of malignant lymphoma. Ann Nucl Med 1994; 8: 187-191.
195. Leskinen-Kallio S, Ruotsalainen U, Nagren K et al. Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: a PET study. J Nucl Med 1991; 32: 1211-1218.
196. Bares R, Galonska P, Dempke W et al. Somatostatin receptor scintigraphy in malignant lymphoma: first results and comparison with glucose metabolism measured by positron-emission tomography. Horm Metab Res Suppl 1993; 27: 56-58.
197. Schonberger JA, Stollfuss JC, Kocher F et al. Whole body 18-FDG-PET for staging of malignant lymphomas. Eur J Nucl Med 1994; 21: 727.
198. Wahl RL, Hawkins RA, Larson SM et al. Proceedings of a national cancer institute workshop: PET in oncology - a clinical research agenda. Radiology 1994; 193: 604-606.
199. Paulus P, Jerusalem G, Warland V et al. Apport de la tomographie à émission de positons (TEP) au 18-FDG corps entier dans le bilan d'extension, l'évaluation de l'efficacité thérapeutique et le suivi clinique des lymphomes hodgkiniens et non-hodgkiniens. Médecine Nucléaire - Imagerie Fonctionnelle et Métabolique 1995; 19: 7/9: 421.
200. 18F-fluorodeoxyglucose in response evaluation and follow-up of Hodgkin's disease and non-Hodgkin's lymphoma [abstract]. Eur J Nucl Med 1995; 22:786.
201. Dimitrakopoulou-Strauss A, Strauss LG, Glodschmidt H et al. Evaluation of tumor metabolism and multidrug resistance in patients with treated malignant lymphomas. Eur J Nucl Med 1994; 21: 727.
202. Minn H, Paul R, Ahonen A. Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18-fluorodeoxyglucose. J Nucl Med 1988; 29: 1521-1525.
203. Leskinen-Kallio S, Lindholm P, Lapela M et al. Imaging of head and neck tumors with positron emission tomography and [C-11] methionine. Int J Radiat Oncol Biol Phys 1994; 30: 1195-1199.
204. Lindholm P, Leskinen-Kallio S, Minn H et al. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine in head and neck cancer. J Nucl Med 1993; 34: 1711-1716.
205. Moreau P, Goffart Y, Collignon J. Computed tomography of metastatic cervical lymph nodes. Arch Otolaryngol Head Neck Surg 1990; 116: 1190-1193.
206. Greven KM, McGuirt WF, Watson X et al. PET in the evaluation of laryngeal carcinoma. Ann Otol Rhinol Laryngol 1995; 104: 274-278.
207. Rege S, Mass A, Chaiken L et al. Use of positron emission tomography with fluorodeoxyglucose in patients with extracranial head and neck cancers. Cancer 1994; 73: 3047-3058.
208. Wong WL, Chevretton E, McGurk M, Croft D. PET-FDG imaging in the clinical evaluation of head and neck cancer. J R Soc Med 1995; 88: P469-P473.
209. Zeitouni AG, Yamamoto YL, Black M, Gjedde A. Functional imaging of head and neck tumors using positron emission tomography. J Otolaryngol 1994; 23: 77-80.
210. Bailet JW, Sercarz JA, Abemayor E et al. The use of positron emission tomography for early detection of recurrent head and neck squamous cell carcinoma in postradiotherapy patients. Laryngoscope 1995; 105: 135-139.
211. Jabour BA, Choi Y, Hoh CK et al. Extracranial head and neck: PET imaging with 2-(F-18)-fluoro-2-deoxy-D-glucose and MR imaging correlation. Radiology 1993; 186: 27-35.
212. McGuirt WF, Greven KM, Keyes JW et al. Positron emission tomography in the evaluation of laryngeal carcinoma. Ann Otol Rhinol Laryngol 1995; 104: 274-278.
213. McGuirt WF, Keyes JW, Greven KM et al. Preoperative identification of benign versus malignant parotid masses: a comparative study including positron emission tomography. Laryngoscope 1995; 105: 579-584.
214. Keyes JW Jr, Harkness BA, Greven KM et al. Salivary gland tumors: pretherapy evaluation with PET. Radiology 1994; 1992: 99-102.
215. Laubenbacher C, Saumweber D, Wagner-Manslau C et al. Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas. J Nucl Med 1995; 36: 1747-1757.
216. Braams JW, Pruim J, Freling NJL et al. Detection of lymph node metastases of squamous-cell cancer of the head and neck with FDG-PET and MRI. J Nucl Med 1995; 36: 211-216.
217. 18F-fluorodeoxyglucose to presurgical loco-regional lymph node staging of head and neck tumors. Eur J Nucl Med 1995; 22: 659.
218. Lee TH, Anzai Y, Huda A et al. Positron emission tomographic imaging of the head and neck. West J Med 1993; 159: 72.
219. Lehmann W, Benchaou M, Slosman DO et al. Positron emission tomography in the preoperative evaluation of cervical lymph node metastasis of ORL cancer. Schweiz Rundsch Med Prax 1993; 82: 1457-1461.
220. Bailet JW, Abemayor E, Jabour BA et al. Positron emission tomography: a new, precise imaging modality for detection of primary head and neck tumors and assessment of cervical adenopathy. Laryngoscope 1992; 102: 281-288.
221. Mancuso AA, Drane WE, Mukherji SK. The promise FDG in diagnosis and surveillance of head and neck cancer. Cancer 1994; 74: 1193-1195.
222. Rege SD, Chaiken L, Hoh CK et al. Change induced by radiation therapy in FDG uptake in normal and malignant structures of the head and neck: quantitation with PET. Radiology 1993; 189: 807-812.
223. Greven KM, Williams DW, Keyes JW et al. Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation. Cancer 1994; 74: 1355-1359.
224. Mukherji SK, Drane WE, Tart RP et al. Comparison of thallium-201 and F-18 FDG SPECT uptake in squamous cell carcinoma of the head and neck. Am J Neuroradiol 1994; 15: 1837-1842.
225. Chaiken L, Rege S, Hoh C et al. Positron emission tomography with fluorodeoxyglucose to evaluate tumor response and control after radiation therapy. Int J Radiat Oncol Biol Phys 1993; 27: 455-464.
226. Greven KM, Williams DW, Keyes JW et al. Distinguishing tumor recurrence from irradiation sequelae with positron emission tomography in patients treated for larynx cancer. Int J Radiat Oncol Biol Phys 1994; 29: 841-845.
227. Haberkorn U, Strauss LG, Reisser C et al. Positron-enemissionstomographie (PET) fur Beurteilung von Tumorproliferation und Therapieverlauf bei HNO-Tumoren. Radiologe 1992; 32: 296-301.
228. Haberkorn U, Strauss LG, Dimitrakopolou A et al. Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy. J Nucl Med 1993; 34: 12-17.
229. Reisser C, Haberkorn U, Dimitrakopoulou-Strauss A et al. Chemotherapeutic management of head and neck malignancies with positron emission tomography. Arch Otolaryngol Head Neck Surg 1995; 121: 272-276.
230. Miller BA, Feuer EJ, Hankey BF. Recent incidence trends of breast cancer in women and the relevance of early detection. An update. CA Cancer J Clin 1993; 43: 27-41.
231. Anderson I, Aspergen K, Janzow L et al. Mammographic screening and mortality from breast cancer: the Malmo Mammographic Screening Trial. Br Med J 1988; 297: 943-948.
232. Boring CC, Suires TS, Tong T. Cancer statistics 1993. CA Cancer J Clin 1993; 43: 7-26.
233. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy, 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 1992; 339: 1-15, 71-85.
234. Danforth DN. The role of axillary lymph node dissection in the management of breast cancer. Principles and Practice of Oncology 1992; 6: 1-16.
235. 18F)fluoro-16α-ethyl-19-norprogesterone as a positron-emitting radiopharmaceutical for the detection of progestin receptors in human breast carcinomas. J Nucl Med 1991; 32: 1532-1537.
236. 18F) fluoro-17β-estradiol uptake in metastatic breast carcinoma. J Nucl Med 1991; 32: 1526-1531.
237. Mintun MA, Welch MJ, Siegel BA et al. Breast cancer: PET imaging of estrogen receptors. Radiology 1988; 169: 45-48.
238. Elston CW. Grading of invasive carcinoma of the breast. In: Page DL, Anderson TJ, eds. Diagnostic histopathology of the breast. New York: Churchill Livingstone, 1987.
239. Paik S, Hazan R, Fisher ES. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 1990; 8: 103-112.
240. Bruce DM, Evans NT, Heys SD et al. Positron emission tomography: 2-deoxy-2-[18F]-fluoro-D-glucose uptake in locally advanced breast cancers. Eur J Surg Oncol 1995; 21: 280-283.
241. Crowe JP, Adler LP, Shenk RR et al. Positron emission tomography and breast masses: comparison with clinical, mammographic and pathological findings. Ann Surg Oncol 1994; 1: 132-140.
242. Dehdashti F, Mortimer JE, Siegel BA et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med 1995; 36: 1766-1774.
243. Tse NY, Hoh CK, Hawkins RA et al. The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann Surg 1992; 216: 27-34.
244. Zasadny KR, Wahl RL. Enhanced FDG-PET tumor imaging with correlation-coefficient filtered influx-constant images. J Nucl Med 1996; 37: 371-374.
245. 18F)Fluorodeoxyglucose scintigraphy in diagnosis and follow-up of treatment in advanced breast cancer. Eur J Nucl Med 1989; 15: 61-66.
246. 18F)fluoro-D-glucose. N Engl J Med 1991; 324: 200.
247. Wahl RL, Cody RL, Hutchins GD, Mudgett EE. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1991; 179: 765-770.
248. 18F)fluorodeoxyglucose and positron emission tomography. J Comput Assist Tomogr 1989; 13: 1097-1098.
249. Nieweg OE, Kim EE, Wong WH et al. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer 1993; 71: 3920-3925.
250. Nieweg OE, Wong WH, Singletary SE et al. Positron emission tomography of glucose metabolism in breast cancer. Potential for tumor detection, staging and evaluation of chemotherapy. Ann NY Acad Sci 1993; 698: 423-428.
251. Adler LP, Crowe JP, Al-Kaisi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with (F-18)2-deoxy-2-fluoro-D-glucose PET. Radiology 1993; 187: 743-750.
252. Adler DD, Wahl RL. New methods for imaging the breast: techniques, findings, and potential. Am J Roentgenol 1995; 164: 19-30.
253. Avril N, Janicke F, Dose J et al. Imaging of breast tumors with FDG-PET in comparison with histology. Eur J Nucl Med 1994; 21: 749.
254. Wahl RL, Helvie MA, Chang AE, Andersson I. Detection of breast cancer in women after augmentation mammoplasty using fluorine-18-fluorodeoxyglucose-PET. J Nucl Med 1994; 35: 872-875.
255. Cady B. The need to reexamine axillary lymph node dissection in invasive breast cancer. Cancer 1994; 73: 505-508.
256. March DE, Wechsler RJ, Kurtz AB et al. CT-pathologic correlation of axillary lymph nodes in breast carcinoma. J Comput Assist Tomogr 1991; 15: 440-444.
257. Adler LP, Cascade E, Crowe J et al. Axillary lymph node involvement in breast cancer: a retrospective study. Abstract from the 1994 ICP Meeting, Institute for Clinical PET, Fairfax, Virginia.
258. Petren-Mallmin M. Clinical and experimental imaging of breast cancer metastases in the spine. Acta Radiol Suppl 1994; 391: 1-23.
259. Wahl Rl, Zasadny K, Helvie M et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography. Initial evaluation. J Clin Oncol 1993; 11: 2101-2111.
260. Jansson T, Westlin JE, Ahlstrom H et al. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation. J Clin Oncol 1995; 13: 1470-1477.
261. Uren RF, Howman-Giles RB, Shaw HM et al. Lymphoscintigraphy in high-risk melanoma of the trunk: predicting draining node groups, defining lymphatic channels and locating the sentinel node. J Nucl Med 1993; 34: 1435-1440.
262. Buzaid AC, Sandler AB, Maani S et al. Role of computed tomography in the staging of primary melanoma. J Clin Oncol 1993; 11: 638-643.
263. Wahl RL, Hutchins GD, Buchsbaum DJ et al. Fluorine-18-2-deoxy-2-fluoro-D- glucose (FDG) uptake into human tumor xenografts: feasibility studies for cancer imaging with PET. Cancer 1991; 67: 1544-1549.
264. Gritters LS, Francis IR, Zasadny KR. et al. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-deoxy-D-glucose in the imaging of malignant melanoma. J Nucl Med 1993; 34: 1420-1427.
265. 265a. Boni R, Boni RA, Steinert H et al. Staging of metastatic melanoma by whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D- glucose. Br J Dermatol 1995; 132: 556-562.
266. 265b. Steinert HC, Boni RAH, Buck A et al. Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D- glucose. Radiology 1995; 195: 705-709.
267. Strauss LG, Dimitrakopoulou-Strauss A, van Kaick G. PET studies with F-18-deoxyglucose in patients with metastatic melanoma prior and after therapy. J Nucl Med 1994; 35: 38P
268. Blessing C, Feine U, Geiger L et al. Positron emission tomography and ultrasonography. A comparative retrospective study assessing the diagnostic validity in lymph node metastases of malignant melanoma. Arch Dermatol 1995; 131: 1394-1398.
269. Bhattathiry M, Glass E, Kirgan D et al. Efficacy of FDG whole body PET in staging and clinical management of metastatic malignant melanoma. J Nucl Med 1994; 35: 230P.
270. Kirgan D, Guenther J, Bhattathiry M et al. The importance of whole-body PET scans on the management of metastatic malignant melanoma. Prog Proc Annu Meet Am Soc Clin Oncol 1994; 13: 396.
271. Yao WJ, Hoh CK, Glaspy JA et al. Whole body FDG PET imaging for staging of malignant melanoma: is it cost effective? J Nucl Med 1994; 35: 8P.
272. Bloom AD, Adler LP, Shuck JM. Determination of malignancy of thyroid nodules with positron emission tomography. Surgery 1993; 114: 728-735.
273. Adler LP, Bloom AD. Positron emission tomography of thyroid masses. Thyroid 1993; 3: 195-200.
274. Joensuu H, Ahonen A, Klemi PJ. 18F-Fluorodeoxyglucose imaging in preoperative diagnosis of thyroid malignancy. Eur J Nucl Med 1988; 13: 502-506.
275. Joensuu H, Ahonen A. Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. J Nucl Med 1987; 28: 910-914.
276. Fridrich L, Messa C, Landoni C et al. PET/(F-18)FDG and I-131 scintigraphy in patients with thyroid carcinoma. Eur J Nucl Med 1994; 2: 780.
277. Scott GC, Meier DA, Dickinson CZ. Cervical lymph node metastasis of thyroid papillary carcinoma imaged with fluorine-18-FDG, technetium-99m- pertechnetate and iodine-131-sodium iodide. J Nucl Med 1995; 36: 1843-1945.
278. 131I. Nuklearmedizin 1995; 34: 127-134.
279. Grunwald F, Schomburg A, Bender H et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1996; 23: 312-319.
280. Sisson JC, Ackermann RJ, Meyer MA et al. Uptake of 18-fluoro-2-deoxy-D- glucose by thyroid cancer: implications for diagnosis and therapy. J Clin Endocrinol Metab 1993; 77: 1090-1094.
281. The Western PET Association. Positron emission tomography. Applications in clinical oncology: an annotated bibliography.
282. Neumann DR, Esselstyn CB, MacIntyre WJ et al. Primary hyperparathyroidism: preoperative parathyroid imaging with regional body FDG PET. Radiology 1994; 192: 509-512.
283. Sisson JC, Thompson NW, Ackerman RJ, Wahl RL. Use of 2-(F-18)-fluoro-2- deoxy-D-glucose PET to locate parathyroid adenomas in primary hyperparathyroidism. Radiology 1994; 192: 280.
284. Shulkin BL, Koeppe RA, Francis IR et al. Pheochromocytomas that do not accumulate metaiodobenzylguanidine: localization with PET and administration of FDG. Radiology 1993; 186: 11-15.
285. Vaidyanathan G, Affleck DJ, Zalutsky MR. Validation of 4-[fluorine-18]fluoro-3-iodobenzylguanidine as a positron-emitting analog of MIBG. J Nucl Med 1995; 36: 644-650.
286. Shulkin BL, Sisson JC, Hutchinson RJ. PET FDG studies of neuroblastoma. J Nucl Med 1994; 35: 135P.
287. Abrams HL, Spiro R, Goldstein N. Metastases in carcinoma: analysis of 1000 autopsied cases. Cancer 1950; 3: 74-85.
288. Dunnick NR. Adrenal imaging: current status. AJR 1990; 154: 927-936.
289. Ahlstrom H, Eriksson B, Bergstrom M et al. Pancreatic neuroendocrine tumors: diagnosis with PET. Radiology 1995; 195: 333-337.
290. Foidart-Willems J, Depas G, Vivegnis D et al. Positron emission tomography and radiolabelled octreotide scintigraphy in carcinoid tumors [abstract]. Eur J Nucl Med 1995; 22: 635.
291. Muhr C, Bergström M. Positron emission tomography applied in the study of pituitary adenomas. J Endocrinol Invest 1991; 14: 509-528.
292. Bergström M, Muhr C, Lundberg PO, Langström B. PET as a tool in the clinical evaluation of pituitary adenomas. J Nucl Med 1991; 32: 610-615.
293. Kern KA, Brunetti A, Norton JA et al. Metabolic imaging of human extremity musculoskeletal tumors by PET. J Nucl Med 1988; 29: 181-186.
294. Nieweg OR, Pruim J, van Ginkel RJ et al. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med 1996; 37: 257-261.
295. Griffeth LK, Dehdashti F, McGuire AH et al. PET evaluation of soft-tissue masses with fluorine-18 fluoro-2-deoxy-D-glucose. Radiology 1992; 182: 185-194.
296. Nieweg OE, Pruim J, Hoekstra HJ et al. Positron emission tomography with fluorine-18-fluorodeoxyglucose for the evaluation of therapeutic isolated regional limb perfusion in a patient with soft-tissue sarcoma. J Nucl Med 1994; 35: 90-92.
297. Jones DN, Brizel DM, Charles HC et al. Monitoring of response to neoadjuvant therapy of soft tissue and musculoskeletal sarcomas using F-18-FDG PET. J Nucl Med 1994; 35: 38P.
298. Tse N, Hoh C, Hawkins R et al. Positron emission tomography diagnosis of pulmonary metastases in osteogenic sarcoma. Am J Clin Oncol 1994; 17: 22-25.
299. Einhorn W, Nilsson B, Stovall K. Factors influencing survival in carcinoma of the ovary. Cancer 1985; 55: 2015-2019.
300. Wahl RL, Hutchins GD, Roberts J. FDG-PET imaging of ovarian cancer: initial evaluation in patients. J Nucl Med 1991: 32: 982.
301. 18F)-deoxyglucose. Gynecol Oncol 1993; 51: 197-204.
302. Hubner KF. Clinical applications of PET in ovarian cancer: an alternative to second look surgery. In: Proceedings 7th Annual International PET Conference, Institute for Clinical PET, Fairfax, Virginia, 1995.
303. 18F)-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma. Gynecol Oncol 1993; 51: 175-181.
304. Casey MJ, Gupta NC, Muths CK. Experience with positron emission tomography (PET) scans in patients with ovarian cancer. Gynecol Oncol 1994; 53: 331-338.
305. Avril N, Janicke F, Dose J et al. FDG-PET evaluation of pelvic masses suspicious for primary or recurrent ovarian cancer. J Nucl Med 1994; 35: 231P.
306. 18F-fluoro-D-glucose in patients with renal cell carcinoma (preliminary report). Kaku Igaku 1988; 25: 1143-1148.
307. Wahl RL, Harney J, Hutchins G, Grossman HB. Imaging of renal cancer using positron emission tomography with 2-deoxy-2-(18F)-fluoro-D-glucose: pilot animal and human studies. J Urol 1991; 146: 1470-1474.
308. 18F) fluoro-D-glucose in bladder cancer: animal localization and initial patient positron emission tomography. J Urol 1991; 145: 279-283.
309. Kocher F, Grimmel S, Hautmann R et al. Preoperative lymph nodes tagging in patients with kidney and urinary bladder neoplasm. J Nucl Med 1994; 35: 223P.
310. Wahl RL, Greenough R, Clarke MF, Grossman HB. Initial evaluation of FDG/PET imaging of metastatic testicular neoplasms. J Nucl Med 1993; 34: 6P.
311. Wilson CB, Young HE, Ott RJ et al. Imaging metastatic testicular germ cell tumours with [18]FDG positron emission tomography: prospects for detection and management. Eur J Nucl Med 1995; 22: 508-513.
312. Wahl RL. Emerging applications of PET in oncology: melanoma, lymphoma and prostate cancer. Proceedings, Sixth Annual International PET Conference, Institute for Clinical PET 1994, Fairfax, Virginia, USA.
313. Laubenbacher C, Hofer C, Avril N et al. Can 18-FDG PET differentiate local recurrent prostatic cancer and scar? Eur J Nucl Med 1995; 22: 803.
314. Shreeve P, Grossman HB, Wahl RL. Initial assessment of FDG/PET detection of skeletal metastatic prostate carcinoma. J Nucl Med 1993; 34: 223P.
315. Delbeke D, Meyerowitz C, Lapidus RL et al. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology 1995; 195: 47-52.
316. Sasaki M, Ichiya Y, Kuwabara Y et al. Ringlike uptake of [18F]FDG in brain abscess: a PET study. J Comput Assist Tomogr 1990; 14: 486-487.
317. 11C] methionine uptake in brain abscess: a PET study. J Comput Assist Tomogr 1993; 17: 660-661.
318. Hoffman JM, Waskin HA, Schifter T et al. FDG-PET in differentiating lymphoma from non malignant central nervous system lesions in patients with AIDS. J Nucl Med 1993; 34: 567-75.
319. 11C-methionine and fluorine-18 FDG PET study in brain hematoma. J Nucl Med 1994; 35: 1162-1166.
320. 68Ga]EDTA in supratentorial tumors. J Comput Assist Tomogr 1985; 9: 683-689.
321. 11C-methionine and computed tomography of intracranial tumours compared with histopathologic examination of multiple biopsies. Acta Radiol 1987; 28: 673-681.
322. 11C-méthionine dans l'étude des tumeurs cérébrales. Cire Metab Cerveau 1992; 9: 205.
323. Ogawa T, Shishido F, Kanno I et al. Cerebral glioma: evaluation with methionine PET. Radiology 1993; 186: 45-53.
324. 11C-methionine. AJNR 1996; 17: 345-353.
325. 18F]FDG uptake in primary cerebral lymphoma: a PET study. J Comput Assist Tomogr 1988; 12: 47-48.
326. Rosenfeld SS, Hoffman JM, Coleman RE et al. Studies of primary central nervous system lymphoma with fluorine-18-fluorodeoxyglucose positron emission tomography. J Nucl Med 1992; 33: 532-536.
327. Di Chiro G, Hatzawa J, Katz DA et al. Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: a PET study. Radiology 1987; 164: 521-526.
328. Francavilla TL, Miletich RS, De Michele D et al. Positron emission tomography of pituitary macroadenomas: hormone production and effects of therapies. Neurosurgery 1991; 28: 826-833.
329. Griffeth LK, Rich KM, Dehdashti F et al. Brain metastases from non-central nervous system tumors: evaluation with PET. Radiology 1993; 186: 37-44.
330. Worthington C, Tyler JL, Villemure JG. Stereotaxic biopsy and positron emission tomography correlation of cerebral gliomas. Surg Neurol 1987; 27: 87-92.
331. Hanson MW, Glantz MJ., Hoffman JM et al. FDG-PET in the selection of brain lesions for biopsy. J Comput Assist Tomogr 1991; 15: 796-801.
332. Levivier M, Goldman S, Bidaut LM. et al. Positron emission tomography-guided stereotactic brain biopsy. Neurosurgery 1992; 31: 792-797.
333. 18F] fluorodeoxyglucose. J Neurosurg 1995; 82: 445-452.
334. 11C]tyrosine positron emission tomography to localization of cerebral gliomas for biopsy. Neurosurgery 1994; 4:1002.
335. Pirotte B, Goldman S, Bidaut LM et al. Use of positron emission tomography (PET) in stereotactic conditions for brain biopsy. Acta Neurochir (Wien) 1995; 134: 79-82.
336. Tyler JL, Diksic M, Villemure JG et al. Metabolic and hemodynamic evaluation of gliomas using positron emission tomography. J Nucl Med 1987; 28: 1123-1133.
337. Heiss WD, Heidel W, Herholtz K et al. Positron emission tomography of fluorine-18-deoxyglucose and image-guided phosphorus-31 magnetic resonance spectroscopy in brain tumors. J Nucl Med 1990; 31: 302-310.
338. Schifter T, Hoffman JM, Hanson MW et al. Serial FDG-PET studies in the prediction of survival in patients with primary brain tumors. J Comput Assist Tomogr 1993; 17: 509-516.
339. Francavilla TL, Miletich RS, De Michele D et al. Positron emission tomography of pituitary macroadenomas: hormone production and effects of therapies. Neurosurgery 1991; 28: 826-833.
340. Patronas NJ, Di Chiro GD, Kufta C et al. Prediction of survival in glioma patients by PET. J Neurosurg 1986; 62: 816-822.
341. Di Chiro G, Brooks RA. PET quantitation: blessing and curse [editorial]. J Nucl Med 1988; 29: 1603-1604.
342. Kim CK, Alavi JB, Alavi A et al. New grading system of cerebral gliomas using positron emission tomography with F-18 fluorodeoxyglucose. J Neurooncol 1991; 10: 85-91.
343. Schmidt KC, Lucignagni G, Sokoloff L. Fluorine-18-fluorodeoxyglucose PET to determine regional cerebral glucose utilization: a re-examination. J Nucl Med 1996; 37: 394-399.
344. Fulham MJ, Melisi JW, Nishimiya J et al. Neuroimaging of juvenile pilocytic astrocytomas: an enigma. Radiology 1993; 189: 221-225.
345. Theodore WH, Di Chiro G, Margolin R et al. Barbiturates reduce human cerebral glucose metabolism. Neurology 1986; 36: 60-64.
346. Ishizu K, Nishizawa S, Yonekura Y et al. Effects of hyperglycemia on FDG uptake in human brain and glioma. J Nucl Med 1994; 35: 1104-1109.
347. Herholtz K, Pietrzyk U, Voges J et al. Correlation of glucose consumption and tumor cell density in astrocytomas. J Neurosurg 1993; 79: 853-858.
348. Fulham MJ, Brunetti A, Aloj L et al. Decreased cerebral glucose metabolism in patients with brain tumors: an effect of corticosteroids. J Neurosurg 1995; 83: 657-664.
349. Patronas NJ, Di Chiro G, Smith BH et al. Depressed cerebellar glucose metabolism in supratentorial tumors. Brain Res 1984; 291: 93-101.
350. 11C-methionine and positron emission tomography. AJNR 1985; 6: 505-514.
351. 11C]L-methionine uptake in gliomas. Neurosurgery 1989; 25: 720-728.
352. Sato K, Kameyama M, Ishiwata K et al. Dynamic study of methionine uptake in glioma using positron emission tomography. Eur J Nucl Med 1992; 19: 426-430.
353. 11C-methionine uptake in brain tumors measured by PET: early clinical results. In: Mazoyer BM, Heiss WD, Comar D, eds. PET studies on amino acids metabolism and protein synthesis. Dordrecht: Kluwer Academic; 1993: 243-254.
354. 11C]methionine. J Comput Assist Tomogr 1983; 7: 1062-1066.
355. Kaschten B, Sadzot B, Stevenaert A. Evaluation of brain tumor metabolism by PET. J Neurooncol 1994; 21: 2.
356. Borbely K, Fulham MJ, Brooks RA et al. PET-fluorodeoxyglucose of cranial and spinal neuromas. J Nucl Med 1992; 33: 1931-1934.
357. Glantz MJ, Hoffman JM, Coleman RE et al. Identification of early recurrence of primary central nervous system tumors by F-18-fluorodeoxyglucose positron emission tomography. Ann Neurol 1991; 29: 347-355.
358. Ito M, Patronas NJ, Di Chiro G et al. Effect of moderate level X-radiation to brain on cerebral glucose utilization. J Comput Assist Tomogr 1986; 10: 584-588.
359. 18F-2-fluoro-2-deoxy)D-glucose. Eur J Nucl Med 1986; 12: 325-328.
360. Kubota K, Matsuzawa T, Takahashi T et al. Rapid and sensitive response of carbon-11-L-methionine tumor uptake to irradiation. J Nucl Med 1989; 30: 2012-2016.
361. Mineura K, Yasuda T, Kowada M et al. Positron emission tomographic evaluations in the diagnosis and therapy of multifocal glioblastoma. Pediatr Neurosci 1985-1986; 12: 208-212.
362. Ogawa T, Uemura K, Kanno I et al. Delayed radiation necrosis of brain evaluated by positron emission tomography. Tokohu J Exp Med 1988; 155: 247-260.
363. Rozental JM, Levine RS, Nickles RJ, Dobkin JA. Glucose uptake by gliomas after treatment. A positron emission tomographic study. Arch Neurol 1989; 46: 1302-1307.
364. Hölzer T, Herholtz K, Jeske J, Heiss WD. FDG-PET as a prognostic indicator in radiochemotherapy of glioblastoma. J Comput Assist Tomogr 1993; 17: 681-687.
365. Holthoff VA, Herholtz K, Berthold F et al. In vivo metabolism of childhood posterior fossa tumors and primitive neuroectodermal tumors before and after treatment. Cancer 1993; 72: 1394-1403.
366. 18F]fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain. Radiology 1982;144: 885-889.
367. Di Chiro G, Oldfield E, Wright DC. et al. Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJNR 1987; 8: 1083-1091.
368. Doyle WK, Budinger TF, Valk PE et al. Differentiation of cerebral radiation necrosis from tumor recurrence by F-18-FDG and Rb-82 positron emission tomography. J Comput Assist Tomogr 1987; 11: 563-570.
369. Valk PE, Budinger TF, Levin VA et al. PET of malignant cerebral tumors after interstitial brachytherapy. Demonstration of metabolic activity and correlation with clinical outcome. J Neurosurg 1988; 69: 830-838.
370. 11C-methionine for diagnosis of recurrent brain tumor and radiation injury. Acta Radiol 1991; 32: 197-202.
371. Ishikawa M, Kikuchi H, Miyatake S et al. Glucose consumption in recurrent gliomas. Neurosurgery 1993; 33: 28-33.
372. 18] fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors. Ann Neurol 1993; 33: 540-548.
373. Mogard J, Kihlström L, Ericson K et al. Recurrent tumor vs radiation effects after gamma knife radiosurgery of intracerebral metastases: diagnosis with PET-FDG. J Comput Assist Tomogr 1994; 18: 177-181.
374. Lilja A, Ludqvist H, Olsson Y et al. Positron emission tomography and computed tomography in differential diagnosis between recurrent or residual glioma and treatment-induced brain lesions. Acta Radiol 1989; 30: 121-128.
375. 11C-methyl-L-methionine positron emission tomography in patients with primary cerebral malignant lymphoma. Neuroradiology 1992; 34: 517-519.